This is further supported by the finding of the group of Sharon Cantor and our data presented here, confirming the PARPi resistance when MDC1 was depleted in human MDA-MB-436 (BRCA1-mutated) [53] and PEO1 (BRCA2-mutated) cancer cells. This evidence concerns the gene BRCA2 and cancer.